Organogenesis (NASDAQ:ORGO) Trading Down 6.1% – Time to Sell?

Organogenesis (NASDAQ:ORGO) fell 6.1% on Tuesday . The stock traded as low as $5.48 and last traded at $5.6250. 982,246 shares were traded during mid-day trading, a decline of 31% from the average session volume of 1,433,160 shares. The stock had previously closed at $5.99.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on ORGO shares. Cantor Fitzgerald raised their target price on Organogenesis from $7.00 to $9.00 and gave the company an “overweight” rating in a report on Friday, August 8th. Wall Street Zen upgraded shares of Organogenesis from a “hold” rating to a “strong-buy” rating in a research note on Saturday, November 8th. BTIG Research reiterated a “buy” rating and issued a $7.00 price target on shares of Organogenesis in a research note on Friday, September 26th. Finally, Weiss Ratings reiterated a “sell (d+)” rating on shares of Organogenesis in a research note on Thursday. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $7.33.

Organogenesis Price Performance

The company has a debt-to-equity ratio of 0.01, a current ratio of 3.32 and a quick ratio of 2.88. The company has a fifty day moving average price of $4.59 and a 200 day moving average price of $4.25. The company has a market capitalization of $705.00 million, a P/E ratio of -46.30 and a beta of 1.68.

Organogenesis (NASDAQ:ORGO) last released its quarterly earnings data on Thursday, November 6th. The company reported $0.18 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.07 by $0.11. The business had revenue of $150.86 million during the quarter, compared to analyst estimates of $134.10 million. Organogenesis had a positive return on equity of 4.01% and a negative net margin of 1.30%. Organogenesis has set its FY 2025 guidance at EPS. On average, sell-side analysts forecast that Organogenesis will post -0.07 EPS for the current fiscal year.

Hedge Funds Weigh In On Organogenesis

Institutional investors and hedge funds have recently bought and sold shares of the stock. PharVision Advisers LLC acquired a new stake in shares of Organogenesis in the 3rd quarter worth approximately $155,000. Quarry LP acquired a new stake in shares of Organogenesis in the third quarter valued at $25,000. First Light Asset Management LLC raised its position in Organogenesis by 10.6% in the third quarter. First Light Asset Management LLC now owns 7,497,911 shares of the company’s stock worth $31,641,000 after acquiring an additional 720,748 shares in the last quarter. Bank of America Corp DE lifted its holdings in Organogenesis by 27.2% in the 3rd quarter. Bank of America Corp DE now owns 611,685 shares of the company’s stock valued at $2,581,000 after acquiring an additional 130,875 shares during the last quarter. Finally, Creative Planning boosted its position in shares of Organogenesis by 8.2% during the 3rd quarter. Creative Planning now owns 38,279 shares of the company’s stock valued at $162,000 after purchasing an additional 2,887 shares in the last quarter. Institutional investors own 49.57% of the company’s stock.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.